Literature DB >> 7912530

Taxol: mechanisms of action and resistance.

S B Horwitz1, D Cohen, S Rao, I Ringel, H J Shen, C P Yang.   

Abstract

Information on the mechanisms of action and of resistance to Taxol, as well as new data from our laboratory on the promoter regions of the genes that encode P-glycoprotein in a murine Taxol-resistant cell line, is discussed. Taxol induces the formation of stable bundles of microtubules, thereby interfering with the normal function of cellular microtubules. The drug can induce the multidrug-resistance (MDR) phenotype that includes the overproduction of P-glycoprotein, a membrane glycoprotein that acts as a drug efflux pump. In human tumors resistant to Taxol, P-glycoprotein could be responsible for maintaining the drug below cytotoxic levels. Analyses of the MDR promoters that are involved in P-glycoprotein expression and overproduction revealed an interesting recombination event in a Taxol-resistant cell line. As an important new clinical agent for the treatment of malignancies, Taxol requires further mechanistic investigations at the preclinical level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7912530

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  75 in total

Review 1.  Tubulin interacting agents: novel taxanes and epothilones.

Authors:  Neeraj R Agrawal; Ram Ganapathi; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

2.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.

Authors:  Jason Konner; Rachel N Grisham; Jae Park; Owen A O'Connor; Gillian Cropp; Robert Johnson; Alison L Hannah; Martee L Hensley; Paul Sabbatini; Svetlana Mironov; Svetlana Miranov; Samuel Danishefsky; David Hyman; David R Spriggs; Jakob Dupont; Carol Aghajanian
Journal:  Invest New Drugs       Date:  2011-11-10       Impact factor: 3.850

4.  Isolation and identification of an anticancer drug, taxol from Phyllosticta tabernaemontanae, a leaf spot fungus of an angiosperm, Wrightia tinctoria.

Authors:  Rangarajulu Senthil Kumaran; Johnpaul Muthumary; Byung-Ki Hur
Journal:  J Microbiol       Date:  2009-02-20       Impact factor: 3.422

Review 5.  Paclitaxel chemotherapy for the treatment of gastric cancer.

Authors:  Junichi Sakamoto; Takanori Matsui; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

6.  Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.

Authors:  Yuefang Wang; Aurora O'Brate; Wei Zhou; Paraskevi Giannakakou
Journal:  Cell Cycle       Date:  2005-12-18       Impact factor: 4.534

7.  A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.

Authors:  Xu Wang; Jun Li; Yuxiang Wang; Lydia Koenig; Ada Gjyrezi; Paraskevi Giannakakou; Edwin H Shin; Mourad Tighiouart; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-07-11       Impact factor: 15.881

8.  Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.

Authors:  Gun-Hee Jang; Na-Yeon Kim; Michael Lee
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

9.  Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.

Authors:  Michiro Susa; Arun K Iyer; Keinosuke Ryu; Edwin Choy; Francis J Hornicek; Henry Mankin; Lara Milane; Mansoor M Amiji; Zhenfeng Duan
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

10.  Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.

Authors:  D Arnold; W Voigt; P Kiewe; C Behrmann; S Lindemann; S Reif; H Wiesinger; M Giurescu; E Thiel; H-J Schmoll
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.